MedPath
HSA Product

SOLIQUA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100UNITS/ML + 50MCG/ML

Product approved by Health Sciences Authority (SG)

Basic Information

SOLIQUA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100UNITS/ML + 50MCG/ML

INJECTION, SOLUTION

Regulatory Information

SIN15540P

September 20, 2018

Prescription Only

Therapeutic

SUBCUTANEOUS

August 10, 2023

May 30, 2025

XA10AE54

Company Information

SANOFI-AVENTIS SINGAPORE PTE. LTD.

SANOFI-AVENTIS SINGAPORE PTE. LTD.

Active Ingredients

Lixisenatide

Strength: 50 μg/mL

Insulin glargine

Strength: 100 units/ml

Detailed Information

Contraindications

**4.3 Contraindications** Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.

Indication Information

**4.1 Therapeutic indications** Soliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors. (For study results with respect to effect on glycaemic control, and the populations studied, see section 4.4 and 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).

© Copyright 2025. All Rights Reserved by MedPath